Navigation Links
ViroPharma to Present at Two June Healthcare Conferences
Date:6/2/2009

EXTON, Pa., June 2 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Colin Broom, MD, vice president and chief scientific officer of ViroPharma, will present at the 30th Annual Goldman Sachs Global Healthcare Conference at 3:45 P.M. ET on Tuesday, June 9, 2009. The conference is being held at the Grand Hyatt in New York City.

ViroPharma also announced that William Roberts, vice president, corporate communications will present at the Jefferies & Company 3rd Annual Healthcare Conference at 10:15 A.M. ET on Thursday, June 18, 2009. The conference is being held at the Mandarin Oriental in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at '/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
2. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
3. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
4. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
5. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
6. ViroPharma to Present at Three November Healthcare Conferences
7. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
8. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
9. ViroPharma to Present at Three October Healthcare Conferences
10. ViroPharma to Present at Three September Healthcare Conferences
11. ViroPharma To Acquire Lev Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... KEEGO HARBOR, Mich. , Sept. 18, 2014  Health ... -based biotech firm investigating early-stage algae bioactive compounds and metabolic ... member to the company,s board of directors. Ms. Nola ... executive and investment advisor joined the board effective September 17, ... have Ms. Masterson agree to join our board," states ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Industry Report, 2014-2017" report to their offering. ... can differentiate into specialized cells and can divide (through ... can be applied to treatment of cardiovascular diseases, leukemia ... damage or lesion of liver, kidney and other parenchymal ...
(Date:9/18/2014)... Lewisville, TX (PRWEB) September 18, 2014 ... PVC-C, a FM-4910 listed material, to stay competitive ... industries. These high-performance materials ultimately impact product ... company’s President and owner. , Established in 1980 ... held strong as many fabricators have left the ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... of revenue growth ... 2007 Highlights: * Product ... SET pulse oximeter units increase 20% to 116,300 units, IRVINE, Calif., Feb. ... Measure-Through,Motion & Low Perfusion pulse oximetry, today announced its financial,results for both the ...
... Replidyne, Inc.,(Nasdaq: RDYN ) today announced its financial results ... Replidyne reported a net loss of $16.9 million for ... per basic and diluted common share,of $0.63 per share, compared ... and diluted common share, for the quarter ended December 31, ...
... Market Research,a global provider of pharmaceutical competitive intelligence ... critical strategic insight,for pharma and biotech companies with ... therapies., In this report, entitled MedPredict Thought ... global Thought Leader Panel,debates tough questions facing drug ...
Cached Biology Technology:Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 2Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 3Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 4Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 5Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 6Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 7Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 8Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 9Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 10Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 11Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 12Replidyne Announces 2007 Fourth Quarter and Full Year Results 2Replidyne Announces 2007 Fourth Quarter and Full Year Results 3Replidyne Announces 2007 Fourth Quarter and Full Year Results 4Replidyne Announces 2007 Fourth Quarter and Full Year Results 5Replidyne Announces 2007 Fourth Quarter and Full Year Results 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 7Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report 2
(Date:9/18/2014)... icy moon of Uranus, is one of the most ... Despite its relatively small size, Miranda appears to have ... the formation of at least three remarkable and unique ... These coronae are visible in Miranda,s southern hemisphere, and ... corona, the largest, has ridges and troughs with up ...
(Date:9/18/2014)... University and the Quebec government have discovered microplastics ... Journal of Fisheries and Aquatic Sciences . , ... or industrial cleansers, to which they are commonly ... and buoyancy, they may readily pass through sewage ... in the world,s oceans, but have only recently ...
(Date:9/18/2014)... The fall foliage season that prompts millions of Americans to ... later and possibly last a little longer within a century, ... leaf peeping in some areas of the United States as ... report in the journal Global Ecology and Biogeography . ... that is the state tree of New Hampshire could ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Microplastic pollution discovered in St. Lawrence River sediments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4
... the laboratory of Assistant Professor Frank J. Slack at Yale ... is regulated in lung cancer, presenting new possibilities for diagnosis ... the journals Cell and Developmental Cell. , The oncogene Ras ... where it is over-expressed or activated by mutation. According to ...
... prevented allergic reactions in laboratory mice, as well as ... California, Los Angeles (UCLA) researchers report in the April ... future, the investigators say, these promising results could lead ... allergies, but also possibly for severe food allergies such ...
... dead bone of a transplanted skeletal graft into living tissue ... therapy to stimulate the body into treating the foreign splint ... of cancer and trauma patients each year who suffer with ... Feb. 13 and will appear in the March 1 issue ...
Cached Biology News:Yale Scientists Find MicroRNA Regulates Ras Cancer Gene 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 3Gene therapy converts dead bone graft to new, living tissue 2Gene therapy converts dead bone graft to new, living tissue 3Gene therapy converts dead bone graft to new, living tissue 4
... The Fluorescence Test Plate consists of ... format, with Inert Organic Fluorescent Compounds embedded ... be used on BioTeks FLx800 and Synergy ... ideal for GLP compliance while reducing the ...
... Feature Extraction Software reads and ... to prepare microarray data for ... * one 2-year license ... NFP/Academic accounts , * ...
... Stain combo offers these benefits: ... Offers a safer and ... Eliminates risks to yourself, the environment and your ... bp to >30 kb. UltraPure Agarose is a standard ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
Biology Products: